Rheumatoid Arthritis Treatment Approved For Release... Arava
Rheumatoid arthritis is a chronic illness that causes inflammation of the joints and the tissue around them as well as inflammation of other organs in the body. The inflammation of the joints can be crippling and lead to deformity.
Rheumatoid arthritis is a common rheumatic disease, affecting more than two million people in the United States. The disease is three times more common in women than in men. It afflicts people of all races equally. The disease can begin at any age, but most often starts after age forty and before sixty. In some families, multiple members can be affected, suggesting a genetic contribution to the disorder.
In September, 1998 the U.S. Food & Drug Administration approved Arava (leflunomide) as a new treatment for active rheumatoid arthritis in adults. The drug does not cure rheumatoid arthritis but clinical trials have shown that it does provide relief for painful, swollen joints caused by rheumatoid arthritis and also seems to retard damage to joints.
MedicineNet has learned that 6 studies of Arava patient trials will
be presented at the national meeting of arthritis experts (American
College of Rheumatology) November 8-12 in San Diego, California.
These studies support the use of Arava as a significant additional
weapon against rheumatoid arthritis. Arava compared favorably with
medicines currently used, including sulfasalazine and methotrexate.